研究的机会 utilizing data from the AHA COVID-19心血管疾病登记处

As the severity of the coronavirus pandemic began to reveal itself in the United States, the 美国心脏协会’s 遵循指南 (GWTG) quality improvement program took swift action. 几周后, COVID-19-specific data elements were added to existing GWTG Registry modules for stroke, heart failure, 心房纤颤, 冠状动脉疾病, 和复苏. Early reports describing the association of COVID-19 with significant adverse cardiovascular outcomes and serious complications for patients with existing cardiovascular disease (CVD) or CVD risk factors highlighted the urgent need for additional research.

美国心脏协会的回应是 启动多中心COVID-19心血管疾病注册表，于2020年4月由“遵循指南”提供支持. 这个注册表收集生物标记物, clinical data, 和COVID-19患者的心血管结局, allowing participating sites to examine data in real-time and contribute to a database to study the impact of the pandemic for years to come. The robust GWTG registry infrastructure has allowed for rapid data collection, 包括超过28个,000个病人记录和近130个,000份实验室报告, 有超过150个注册网站注册 .

“Research is key to tracking the effectiveness of treatments and patterns in patient outcomes. Having access to this rapidly growing data set provides the potential for multiple teams to develop simultaneous breakthroughs on multiple fronts,” 詹姆斯·德·莱莫斯解释道.D., co-chair of the steering committee for the registry and professor of medicine and the Sweetheart Ball-Kern Wildenthal, M.D., Ph.D., Distinguished Chair in Cardiology at the University of Texas Southwestern Medical Center in Dallas. “This is instrumental in helping health care professionals gather the evidence needed to rapidly adjust protocols for COVID-19 patients and reflects the importance of the 美国心脏协会’s COVID-19 CVD registry.”

作为质量改进计划, 研究者主导的研究机会使用集合, national dataset were initially provided to investigators at institutions participating in the Registry. These early studies have already provided a robust source of data to inform clinical practice to potentially improve patient outcomes. 美国心脏协会(AHA)展示了最新的进展 科学会议, describing initial results from the registry including racial and ethnic differences in treatment and outcomes and association of body mass index with cardiovascular outcomes in COVID-19 patients. Several additional studies will be published in the peer review literature in the coming weeks and months.

The AHA is pleased to now offer COVID-19心血管疾病登记处 research opportunities to the broader research community, 无论注册中心是否参与. Proposals are accepted on a rolling basis and will be evaluated on priority, 对科学文献的新贡献, 所收集数据的可行性, and merit.

利用这些数据发表了几项高质量的研究. These studies have greatly contributed to our collective knowledge on how best to care for patients hospitalized with COVID, 包括有合并症的患者, 易受伤害的患者群体面临更大的不良健康结果风险, 以及对COVID患者的住院护理质量. 找到这些出版物 提高质素刊物图书馆.

建议及检讨程序:

• 注意:注册中心将从2022年夏季开始不再收集数据.
• 在起草和提交研究计划之前, 请查看COVID-19心血管疾病登记处收集的数据要素 个案报告表格(CRF)  to ensure study feasibility of the analysis based on the data collected in the Registry.
• 下载并完成 COVID-19 CVD注册建议表 
• 将提案提交给美国心脏协会 (电子邮件保护)
• Proposals will be reviewed on a rolling basis by the 美国心脏协会 COVID-19 Research and Publications (R&P)委员会，并将优先评估, 对科学文献的新贡献, 所收集数据的可行性, and merit.
• 每一个被批准的项目将被指派一名R&P委员会支持项目从提案到出版.

In alignment with AHA’s efforts to accelerate research impact and streamline research collaboration, 这些数据将在 AHA精准医疗平台 (PMP). 这个云计算平台, 由美国心脏协会精密心血管医学研究所主办, offers secure workspaces equipped with state-of-the-art analytical tools.

• Proposed analyses should be completed within four weeks of access to data on the Precision Medicine Platform.
• Researchers who have a web-based SAS license or are familiar with other programming languages can conduct their approved analyses in a secured workspace on the Precision Medicine Platform.
• Researchers may also connect with 美国心脏协会 Data Scientists who offer consultative data analytics services to conduct the approved statistical analysis on the Precision Medicine Platform.

在完成对COVID-19心血管疾病登记处数据的建议分析后, 研究人员将起草一份同行评议的手稿.

• The study's lead author will secure approval from all co-authors prior to submitting the manuscript for final approval by the Steering Committee and 美国心脏协会 Science.
• Manuscripts should be drafted and submitted for Steering Committee approval within eight weeks of access to data on Precision Medicine Platform.

Note: No unauthorized data analyses may be conducted using the COVID-19心血管疾病登记处 without proposal review by the AHA COVID-19 Steering Committee and written approval from the 美国心脏协会. All publications must follow AHA’s 质量改进 Program publication guidelines. 更多信息请访问 yirk832.eqmufflerandtow.com/qualityresearch.